Sai Parenteral's
Symbol: SAIPARENT | Industry: Biotechnology & Drugs
Grey Market Premium (GMP)
GMP ACTIVE+₹0.00
Updated: Recent₹392.00
Based on Max Price: ₹392.00+0.00%
Projections onlyIPO Quick Highlights
IPO Timeline
- IPO Opens 24 Mar 2026
- IPO Closes 27 Mar 2026
- Allotment Date 28 Mar 2026
- Listing Date 02 Apr 2026
About the Company
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. It is in the business of branded generic formulations and contract development and manufacturing organizational products and services for the domestic and international markets. Its portfolio includes formulation products across various therapeutic areas like cardiovascular, neruopsychiatry, anti-diabetic, respiratory health, antibiotics, vitamins, minerals and supplements analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, the Company has capabilities in sterile manufacturing for critical care and antibiotics, which are delivered through dry powder injections, pre-filled syringes, ampules, and vials. It manufactures and sells branded generic formulations to a diverse customer base, including central and state government agencies.
Promoters & Key Management
| Rank | Officer Name | Designation | Age | Since |
|---|---|---|---|---|
| #1 | Anil Kumar Karusala | Executive Chairman, Managing Director | 52 | 2024 |
| #2 | D.B.Venkoji Prakash | Chief Executive Officer | - | 2025 |
| #3 | Anil Kumar | Chief Financial Officer | - | 2025 |
| #4 | Shivali Aggarwal | Company Secretary, Compliance Officer | - | 2024 |
| #5 | Vijitha Gorrepati | Whole Time Director | 49 | 2024 |
Financial Performance
Values in ₹ Crores| Key Metric | FY 2023 | FY 2024 | FY 2025 | FY 2026 | Trend |
|---|---|---|---|---|---|
| Total Revenue | 96.80 | 153.76 | 163.11 | 381.00 | Growth |
| Profit After Tax (PAT) | 4.38 | 8.42 | 14.45 | 14.26 | Decline |
| Operating Margin (%) | 13.33% | 14.47% | 19.44% | 5.73% | Down |
| Total Assets | 133.96 | 268.10 | 272.39 | 1,424.23 | - |
| Net Worth | 31.49 | 74.55 | 93.67 | 490.77 | - |
| Borrowings (Debt) | 68.55 | 118.79 | 93.95 | 333.32 | - |
| Debt to Equity Ratio | 2.18 | 1.59 | 1.00 | 0.68 | - |
IPO Valuation
IPO Lot Size Details
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Minimum) | 1 Lot | 1 Shares | ₹392.00 |
| Retail (Maximum) | 510 Lots | 510 Shares | ₹199,920.00 |
| Small HNI (sNII - Min) | 511 Lots | 511 Shares | ₹200,312.00 |
| Small HNI (sNII - Max) | 2551 Lots | 2551 Shares | ₹999,992.00 |
| Big HNI (bNII - Min) | 2552 Lots | 2552 Shares | ₹1,000,384.00 |
Peer Companies Comparison
| Company | CMP (₹) | P/E Ratio | P/B Ratio | Market Cap |
|---|---|---|---|---|
| Sai Parenteral's (This IPO) | ₹392.00 | 141.88 | 5.57 | ₹2,681 Cr. |
| Sun Pharmaceutical Industries | ₹1,913.00 | 33.81 | 5.38 | ₹458,982 Cr. |
| Divi's Laboratories | ₹6,850.80 | 76.97 | 11.28 | ₹181,894 Cr. |
| Torrent Pharmaceuticals | ₹4,826.00 | 72.29 | 18.36 | ₹163,427 Cr. |
| Dr Reddy's Laboratories | ₹1,368.75 | 19.38 | 3.27 | ₹114,241 Cr. |
| Lupin | ₹2,490.00 | 31.36 | 6.09 | ₹113,851 Cr. |
